Your browser is no longer supported. Please, upgrade your browser.
Settings
REGN Regeneron Pharmaceuticals, Inc. daily Stock Chart
REGN [NASD]
Regeneron Pharmaceuticals, Inc.
IndexS&P 500 P/E162.25 EPS (ttm)3.15 Insider Own0.30% Shs Outstand103.28M Perf Week-1.57%
Market Cap52.78B Forward P/E38.01 EPS next Y13.45 Insider Trans-33.23% Shs Float76.01M Perf Month0.43%
Income358.70M PEG8.11 EPS next Q2.78 Inst Own73.20% Short Float6.03% Perf Quarter15.84%
Sales3.06B P/S17.23 EPS this Y-19.40% Inst Trans1.28% Short Ratio6.03 Perf Half Y25.16%
Book/sh29.07 P/B17.58 EPS next Y20.36% ROA9.40% Target Price511.71 Perf Year68.46%
Cash/sh7.19 P/C71.12 EPS next 5Y20.00% ROE13.70% 52W Range295.76 - 544.00 Perf YTD24.58%
Dividend- P/FCF240.15 EPS past 5Y41.20% ROI12.50% 52W High-6.05% Beta0.85
Dividend %- Quick Ratio4.10 Sales past 5Y49.40% Gross Margin92.00% 52W Low72.80% ATR11.89
Employees2925 Current Ratio4.30 Sales Q/Q39.00% Oper. Margin30.60% RSI (14)51.55 Volatility2.18% 2.48%
OptionableYes Debt/Eq0.16 EPS Q/Q8.20% Profit Margin11.70% Rel Volume0.49 Prev Close506.51
ShortableYes LT Debt/Eq0.16 EarningsAug 04 BMO Payout0.00% Avg Volume759.92K Price511.08
Recom2.00 SMA20-0.64% SMA502.59% SMA20018.75% Volume374,927 Change0.90%
Jun-15-15Reiterated RBC Capital Mkts Outperform $543 → $550
Jun-10-15Reiterated Chardan Capital Markets Buy $560 → $565
May-20-15Reiterated Canaccord Genuity Buy $525 → $600
May-20-15Reiterated Argus Buy $500 → $560
May-19-15Reiterated Brean Capital Buy $507 → $525
May-15-15Reiterated JP Morgan Neutral $427 → $450
May-08-15Reiterated UBS Neutral $412 → $500
May-08-15Reiterated Canaccord Genuity Buy $460 → $525
May-08-15Reiterated Brean Capital Buy $450 → $507
May-07-15Reiterated ROTH Capital Neutral $461 → $490
May-06-15Reiterated Leerink Partners Outperform $527 → $559
Apr-29-15Reiterated RBC Capital Mkts Outperform $490 → $533
Apr-24-15Reiterated Leerink Partners Outperform $445 → $527
Mar-27-15Reiterated Argus Buy $450 → $500
Mar-20-15Initiated Chardan Capital Markets Buy $560
Feb-19-15Downgrade ROTH Capital Buy → Neutral $461
Feb-17-15Reiterated Argus Buy $430 → $450
Feb-11-15Reiterated UBS Neutral $417 → $412
Feb-11-15Reiterated RBC Capital Mkts Outperform $480 → $490
Feb-02-15Reiterated RBC Capital Mkts Outperform $477 → $480
Jul-01-15 04:12PM  What Is Beyond Vision-Loss Blockbuster For Regeneron? at Investor's Business Daily
03:21PM  Robbins Arroyo LLP Is Investigating Regeneron Pharmaceuticals, Inc. (REGN) Officials on Behalf of Shareholders PR Newswire
10:27AM  10 Best S&P 500 Health Care Stocks at TheStreet
Jun-30-15 08:00AM  New Film Documents Heart Felt Stories of People Living with High LDL Cholesterol PR Newswire
Jun-29-15 04:40PM  Regeneron/Bayer's Eylea Gets Label Expansion in Japan - Analyst Blog
03:00PM  Regeneron Rapid Response Platform for Emerging Infectious Diseases Described in Proceedings of the National Academy of Sciences Publication PR Newswire
Jun-27-15 06:32PM  WEEKEND VIDEO: Market Positives and Negatives
Jun-26-15 03:00AM  EYLEA® (aflibercept) Injection Receives Approval in Japan for the Treatment of Retinal Vein Occlusion PR Newswire
Jun-25-15 08:30AM  Regeneron Announces 2015 Winners of the Regeneron Prize for Creative Innovation PR Newswire
Jun-23-15 05:02PM  Veteran Investor Sam Isaly Picks Top Biotechs at Barrons.com
06:00AM  5 Biotech Stocks to Trade for Gains at TheStreet
Jun-21-15 03:19PM  Weekend Market VIDEO: Apple, Stocks to Watch, and Biotech
Jun-18-15 06:11PM  IBD Market Wrap - 06/18/15
12:12PM  Fitbit surges on debut; Oracle slumps after earnings at MarketWatch
Jun-17-15 04:19PM  REGENERON PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to
Jun-16-15 11:09AM  Why Avalanche's Disappointing Trial is Good News for Regeneron at Barrons.com
02:39AM  Edited Transcript of REGN shareholder or annual meeting 12-Jun-15 2:30pm GMT
Jun-15-15 11:49PM  Is Amgen About to Enter a Battle Over Billions? at Investopedia
05:27PM  Avalanche eye therapy meets safety goal; vision improvement modest
04:43PM  Avalanche eye gene therapy meets safety goal
10:16AM  Regeneron: Don't Worry, Be Happy at Barrons.com
01:00AM  AXON, REGN, BURL, FIVE: Jim Cramer's Views at TheStreet
Jun-12-15 08:00PM  IBD Market Wrap - 06/12/15
09:00AM  Steven Nissen, Conflicts Of Interest, And The New Cholesterol Drugs at Forbes
Jun-11-15 06:57PM  Cramer: Massive biotech moves that make sense at CNBC
03:42PM  Why Is Amgen Rising And Regeneron Falling? at Barrons.com
08:59AM  Krispy Kreme pops; Lululemon founder sells stake; Nike inks NBA deal
08:10AM  Retail sales rebound; Nike's big NBA score; LA minimum wage hike
Jun-10-15 06:10PM  FDA panel backs Amgen cholesterol drug for some patients
05:35PM  Amgen Cholesterol Drug Repatha Wins FDA Panel Vote at Investor's Business Daily
04:40PM  Regeneron/Sanofi's Praluent Gets Positive FDA Panel Vote - Analyst Blog
04:38PM  Regeneron: Is Biotech Star In Danger of a Bigger Fall? at Barrons.com
04:37PM  FDA panel backs Amgen's cholesterol drug for high-risk patients Reuters
03:26PM  Live Blog: FDA Panel For Amgen's Cholesterol Drug Repatha at Forbes
02:58PM  Esperion sinks
01:35PM  Esperion Therapeutics: Why Regeneron Decision is Bad News at Barrons.com
12:49PM  Why a FDA nod isn't enough for Regeneron shares at CNBC
11:59AM  Selling The News In Regeneron
10:52AM  FDA Panel Clears Product Path For Sanofi, Regeneron Pharmaceuticals
10:52AM  Jim Cramer -- Investors Should Be Patient on Regeneron Cholesterol Drug at TheStreet
10:24AM  Biotech Stock Roundup: FDA Panel Recommends Regeneron's Praluent, SAGE Gains on Data - Analyst Blog
10:16AM  Why Regeneron is Getting Clobbered at Barrons.com
09:28AM  Cramer's Mad Dash: Regeneron
09:10AM  Netflix hits fresh 52-week high; Apple Music probe; HCC surges on merger
08:15AM  Wall Street's funk; Target's dividend slip up; Apple's antitrust problem
07:21AM  Two drugs target 'bad' cholesterol: CEO
Jun-09-15 07:20PM  FDA panel backs first-in-class cholesterol drug
07:16PM  New heart drugs set to add billions to US healthcare bill at Financial Times
06:40PM  FDA Advisory Committee Recommends Approval of Sanofi and Regeneron's Praluent® (alirocumab) Injection for Patients with Hypercholesterolemia PR Newswire
06:30PM  FDA Advisory Committee Recommends Approval of Regeneron and Sanofi's Praluent® (alirocumab) Injection for Patients with Hypercholesterolemia PR Newswire
06:09PM  Regeneron/Sanofi Cholesterol Drug Wins FDA Panel Vote at Investor's Business Daily
06:09PM  Regeneron Cholesterol Fighter Gets FDA Panel's Backing, 13-3
05:32PM  Why Industry Loves Company: Leading Stocks Travel In Groups
05:25PM  Cholesterol drug wars
04:16PM  FDA to make ruling on new cholesterol drugs
04:16PM  FDA panel backs cholesterol drug
01:01PM  Battling 'bad' cholesterol
09:15AM  FDA Looking at New Drugs to Lower "Bad" Cholesterol at Fox Business
07:05AM  Trading in Regeneron Common Stock Halted PR Newswire
06:31AM  FDA targets 'bad' cholesterol drug
Jun-08-15 04:43PM  10 drugs to hit fed budget by $50B over decade at CNBC
11:10AM  Regeneron/Sanofi's PCSK9 Drug Praluent Set for FDA Panel - Analyst Blog
12:08AM  FDA Queues Up Review of Anti-Cholesterol Drugs at The Wall Street Journal
Jun-07-15 04:10PM  REUTERS BUSINESS NEWS SCHEDULE AT 2000 GMT/4 PM ET
09:40AM  New Mega-Blockbuster Cholesterol Drug Class Faces Make-or-Break FDA Panels at 24/7 Wall St.
Jun-06-15 08:02AM  Are 4 Top-Rated IBD 50 Drug Stocks On Your Radar? at Investor's Business Daily
05:33AM  FDA Reviews Anti-Cholesterol Drugs at The Wall Street Journal
Jun-05-15 05:16PM  FDA weighs approval of first-in-class cholesterol drug
04:54PM  Regeneron/Sanofi Cholesterol Drug Under FDA Scrutiny at Investor's Business Daily
10:44AM  The Fight Against Cholesterol Heats Up; FDA Panel Considers Drugs from Regeneron, Amgen Next Week at Barrons.com
09:36AM  FDA Staff Says Sanofi Drug Cuts Cholesterol, Questions Benefit at Bloomberg
Jun-04-15 05:25PM  Fighting 'bad' cholesterol
02:57PM  Alexion: Don't Fear the Competition at Barrons.com
May-29-15 06:53PM  Ambarella, Avago Top An Outperforming IBD 50 List at Investor's Business Daily
04:53PM  R&D Can Be A Critical Factor In Generating Future Profits
May-28-15 08:02AM  Regeneron, Lannett Among The 4 Top-Rated Drug Stocks at Investor's Business Daily
May-26-15 07:14PM  Amgen Gets 1 Step Closer to Another Blockbuster at Investopedia
03:58PM  Amazon, Apple and Chipotle Too Pricey for Your Portfolio? There's an ETF for That at TheStreet
01:00AM  Fight over hot new cholesterol drugs may be won in milligrams Reuters
May-23-15 09:30AM  The Most Loved Biotechs of Big Hedge Funds at 24/7 Wall St.
08:10AM  What You May Have Missed in Biotech: Eye Drug Fails, Ear Drug Flops, and Herpes Drug Succeeds at Forbes
May-21-15 04:27PM  3 Top IBD 50 Stocks Hit New All-Time Highs
10:30AM  Regeneron-Sanofi's Sarilumab Meets Endpoints in Phase III - Analyst Blog
01:00AM  Regeneron and Sanofi Announce Positive Topline Results from Phase 3 Studies with Sarilumab in Patients with Rheumatoid Arthritis PR Newswire
May-20-15 07:00PM  Cramer: This is the absolute worst thing in this market
06:12PM  Cramer: Bail out now on this group at CNBC
11:07AM  Jim Cramer -- Regeneron Will Go Higher; Sarepta Is Rallying at TheStreet
09:34AM  Move Over Chip Stocks: Here Are 5 Top Biotechs at Investor's Business Daily
09:29AM  10 S&P 500 Companies to Have the Most Revenue Growth in 2015 at TheStreet
09:23AM  Cramer's Mad Dash: Regeneron goes higher
May-19-15 07:00PM  Cramer: This went from $5 to $500 and isn't done
04:51PM  Healthcare Winners and Losers: May 19, 2015
04:40PM  Regeneron/Sanofi Announce Positive Data on Dupilumab - Analyst Blog
12:38PM  Regeneron Shares Seen Reaching $525 at Barrons.com
12:04PM  Amgen cholesterol drug could get EU green light this week Reuters
May-18-15 12:30PM  Regeneron and Sanofi Announce Positive Pivotal Phase 2b Dupilumab Data in Asthma Presented at the American Thoracic Society 2015 International Conference PR Newswire
11:33AM  Regeneron: Why It's Heading to $550 at Barrons.com
08:03AM  Is the Stock Market Due for a Correction?
07:39AM  How to play weak Q2 earnings season: Analysts at CNBC
May-15-15 06:13PM  Health Care Sector Delivers Healthy Q1 Results at Investor's Business Daily
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. Its marketed products include EYLEA injection for the treatment of neovascular age-related macular degeneration (AMD) and macular edema; ZALTRAP, an injection for intravenous infusion for the treatment of patients with metastatic colorectal cancer; and ARCALYST, an injection for subcutaneous use for the treatment of cryopyrin-associated periodic syndromes comprising familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children. The company's trap-based clinical product candidates comprise EYLEA for the treatment of AMD and diabetic macular edema; and ZALTRAP for oncology. Its antibody-based clinical programs include various human monoclonal antibody product candidates, such as REGN727 for low-density lipoprotein cholesterol reduction and for the prevention of cardiovascular events; REGN88 for rheumatoid arthritis and non-infectious uveitis; REGN668 for atopic dermatitis, asthma, nasal polyposis, and eosinophilic esophagitis; REGN2222 for respiratory syncytial virus; REGN1033 for skeletal muscle disorders; and REGN2176-3 and REGN910-3 antibodies for use in ophthalmology. The company is also developing REGN1908-1909, REGN1154, REGN1500, and REGN1193 antibody product candidates; REGN1400, REGN1979, and REGN2810 for oncology; and REGN475 for the treatment of pain. It has strategic collaboration with Sanofi to discover, develop, and commercialize human monoclonal antibodies; and license and collaboration agreement with Bayer HealthCare for the development and commercialization of EYLEA, as well as with Avalanche Biotechnologies, Inc. to discover, develop, and commercialize novel gene therapy products for the treatment of ophthalmologic diseases. The company was founded in 1988 and is headquartered in Tarrytown, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GOLDSTEIN JOSEPH LDirectorJun 22Sale526.852,0001,053,70018,000Jun 22 05:02 PM
SING GEORGE LDirectorMay 27Option Exercise19.695,00098,450117,772May 29 04:19 PM
INGRAM ROBERT ALEXANDERDirectorMay 27Sale513.391,379707,9651,500May 27 04:02 PM
SING GEORGE LDirectorMay 27Sale515.005,0002,575,000112,772May 29 04:19 PM
McCorkle Douglas SVP Controller and Asst TreasurMay 22Option Exercise174.0113,4642,342,90217,481May 26 04:31 PM
INGRAM ROBERT ALEXANDERDirectorMay 22Option Exercise293.536,6671,956,9656,667May 27 04:02 PM
McCorkle Douglas SVP Controller and Asst TreasurMay 22Sale515.6013,0006,702,8004,481May 26 04:31 PM
GOLDSTEIN JOSEPH LDirectorMay 22Sale514.284,0002,057,10020,000May 26 04:30 PM
BROWN MICHAEL SDirectorMay 15Option Exercise57.115,000285,5505,000May 18 04:50 PM
BROWN MICHAEL SDirectorMay 15Sale495.005,0002,475,0000May 18 04:50 PM
Landry Robert ESVP Finance & CFOApr 08Option Exercise272.7010,0002,727,00015,000Apr 09 04:03 PM
BAKER CHARLES ADirectorMar 25Option Exercise18.615,00093,05014,000Mar 26 04:20 PM
LAROSA JOSEPH JSVP General Counsel and SecretMar 25Option Exercise59.203,097183,34215,067Mar 26 04:21 PM
BAKER CHARLES ADirectorMar 25Sale454.965,0002,274,7859,000Mar 26 04:20 PM
Aberman Michael SSVP Strategy Investor RelationMar 24Sale478.994,8432,319,73812,498Mar 25 04:07 PM
Aberman Michael SSVP Strategy Investor RelationMar 18Sale465.003,4421,600,54222,498Mar 19 04:05 PM
Aberman Michael SSVP Strategy Investor RelationMar 17Option Exercise24.0011,398273,55229,998Mar 19 04:05 PM
Terifay Robert JSVP CommercialMar 17Sale451.0110,9934,957,90720,029Mar 18 06:03 PM
LAROSA JOSEPH JSVP General Counsel and SecretMar 16Option Exercise59.2020,2811,200,63528,311Mar 17 04:57 PM
Terifay Robert JSVP CommercialMar 16Option Exercise30.6324,375746,60644,404Mar 18 06:03 PM
LAROSA JOSEPH JSVP General Counsel and SecretMar 16Sale450.0018,3118,239,95010,000Mar 17 04:57 PM
McCorkle Douglas SVP Controller and Asst TreasurFeb 27Sale416.243,0001,248,7204,481Feb 27 04:31 PM
Tessier-Lavigne MarcDirectorFeb 26Option Exercise50.913,000152,7304,187Feb 27 04:32 PM
Tessier-Lavigne MarcDirectorFeb 26Sale421.953,0001,265,8641,187Feb 27 04:32 PM
Aberman Michael SSVP Strategy Investor RelationFeb 24Sale418.483,3741,411,95218,600Feb 25 04:02 PM
Terifay Robert JSVP CommercialFeb 24Sale423.6711,1734,733,66520,029Feb 25 04:01 PM
Aberman Michael SSVP Strategy Investor RelationFeb 23Option Exercise30.637,500229,72526,100Feb 25 04:02 PM
Terifay Robert JSVP CommercialFeb 23Option Exercise30.6324,375746,60644,404Feb 25 04:01 PM
Van Plew Daniel PSVP & General Mgr Industrial OFeb 23Sale427.829,4314,034,75418,705Feb 24 05:08 PM
RYAN ARTHUR FDirectorFeb 20Option Exercise125.7929,2503,679,49876,750Feb 23 04:06 PM
BROWN MICHAEL SDirectorFeb 20Option Exercise57.111,00057,1101,000Feb 23 04:07 PM
GOLDSTEIN JOSEPH LDirectorFeb 20Option Exercise177.825,000889,1009,000Feb 20 04:44 PM
Van Plew Daniel PSVP & General Mgr Industrial OFeb 20Option Exercise21.2520,000425,00038,705Feb 24 05:08 PM
GOLDSTEIN JOSEPH LDirectorFeb 20Sale423.655,0002,118,2624,000Feb 20 04:44 PM
BROWN MICHAEL SDirectorFeb 20Sale422.721,000422,7200Feb 23 04:07 PM
RYAN ARTHUR FDirectorFeb 20Sale423.0129,25012,372,90847,500Feb 23 04:06 PM
Aberman Michael SSVP Strategy Investor RelationFeb 17Sale404.463,6921,493,26618,600Feb 18 04:40 PM
Aberman Michael SSVP Strategy Investor RelationFeb 13Option Exercise24.007,500180,00026,100Feb 18 04:40 PM
SCHLEIFER LEONARD SPresident & CEOJan 02Sale410.581,500615,8670Jan 05 04:56 PM
Powchik PeterSVP Clinical Development & RegJan 02Sale414.0810,8224,481,21410,711Jan 05 04:28 PM
Powchik PeterSVP Clinical Development & RegDec 31Option Exercise52.0325,0001,300,75035,711Jan 05 04:28 PM
Powchik PeterSVP Clinical Development & RegDec 19Option Exercise30.633,26499,97610,711Dec 22 12:09 PM
Van Plew Daniel PSVP & General Mgr Industrial ODec 18Option Exercise30.633,26499,97618,705Dec 19 02:11 PM
McCorkle Douglas SVP Controller and Asst TreasurDec 17Option Exercise30.632,80085,7647,481Dec 18 04:22 PM
McCorkle Douglas SVP Controller and Asst TreasurDec 16Option Exercise49.076,818334,56010,556Dec 17 04:51 PM
GOLDBERG MURRAY ASVP Administration & Asst SecrDec 16Option Exercise30.633,26499,97664,436Dec 18 04:25 PM
STAHL NEILSVP Research and Development SDec 16Option Exercise30.633,26499,9766,541Dec 18 04:25 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriDec 16Option Exercise30.633,26499,976503,264Dec 18 04:23 PM
McCorkle Douglas SVP Controller and Asst TreasurDec 16Sale410.006,8182,795,3804,681Dec 17 04:51 PM
McCorkle Douglas SVP Controller and Asst TreasurDec 15Option Exercise30.631,66851,0916,049Dec 17 04:51 PM
McCorkle Douglas SVP Controller and Asst TreasurDec 15Sale410.761,668685,1444,681Dec 17 04:51 PM
POON CHRISTINE ADirectorNov 25Buy410.00400164,000655Nov 26 01:28 PM
GILMAN ALFRED GDirectorNov 24Option Exercise35.9640,0001,438,55040,000Nov 25 04:16 PM
GILMAN ALFRED GDirectorNov 24Sale408.4440,00016,337,5850Nov 25 04:16 PM
STAHL NEILSVP Research and Development SNov 24Sale409.782,200901,5233,277Nov 24 04:15 PM
STAHL NEILSVP Research and Development SNov 21Sale415.163,1071,289,9025,477Nov 24 04:15 PM
STAHL NEILSVP Research and Development SNov 18Option Exercise115.2916,7571,931,91530,284Nov 20 04:14 PM
Terifay Robert JSVP CommercialNov 18Sale405.7922,3629,074,20020,029Nov 19 04:41 PM
Terifay Robert JSVP CommercialNov 17Option Exercise21.2548,7501,035,93868,779Nov 19 04:41 PM
Van Plew Daniel PSVP & General Mgr Industrial ONov 13Sale399.348,5753,424,33615,441Nov 14 04:32 PM
GOLDSTEIN JOSEPH LDirectorNov 12Option Exercise177.825,000889,1009,000Nov 12 05:15 PM
Van Plew Daniel PSVP & General Mgr Industrial ONov 12Option Exercise21.2518,700397,37534,141Nov 14 04:32 PM
GOLDSTEIN JOSEPH LDirectorNov 12Sale398.315,0001,991,5504,000Nov 12 05:15 PM
SCHLEIFER LEONARD SPresident & CEONov 12Sale400.3242,32416,943,28542,087Nov 12 05:14 PM
SCHLEIFER LEONARD SPresident & CEONov 11Sale400.003,4931,397,20084,411Nov 12 05:14 PM
SCHLEIFER LEONARD SPresident & CEOOct 31Sale400.113,4531,381,58087,904Nov 04 04:06 PM
SCHLEIFER LEONARD SPresident & CEOOct 28Sale404.0169,11227,921,80691,357Oct 29 04:27 PM
SCHLEIFER LEONARD SPresident & CEOOct 27Option Exercise19.40256,8084,982,219292,893Oct 29 04:27 PM
BROWN MICHAEL SDirectorOct 24Option Exercise57.115,000285,5505,000Oct 24 04:07 PM
GOLDBERG MURRAY ASVP Administration & Asst SecrOct 24Sale400.7026,78810,734,01863,102Oct 27 04:17 PM
BROWN MICHAEL SDirectorOct 24Sale399.005,0001,995,0000Oct 24 04:07 PM
GOLDBERG MURRAY ASVP Administration & Asst SecrOct 23Option Exercise30.6360,0001,837,800123,102Oct 27 04:17 PM
VAGELOS P ROYChairman of the BoardSep 10Sale350.0710,3263,614,82392,947Sep 10 04:00 PM
VAGELOS P ROYChairman of the BoardSep 08Sale351.002702103,273Sep 10 04:00 PM
McCorkle Douglas SVP Controller and Asst TreasurAug 27Option Exercise21.561,68136,2474,681Aug 28 02:39 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriAug 27Option Exercise314.315,7201,797,853505,720Aug 29 03:29 PM
Tessier-Lavigne MarcDirectorAug 27Option Exercise50.913,000152,7304,187Aug 27 05:02 PM
GOLDSTEIN JOSEPH LDirectorAug 27Sale350.312,000700,6204,000Aug 27 05:01 PM
Tessier-Lavigne MarcDirectorAug 27Sale352.203,0001,056,6001,187Aug 27 05:02 PM
Tessier-Lavigne MarcDirectorAug 26Option Exercise50.911,38770,6121,387Aug 27 05:02 PM
Aberman Michael SVP Strategy and Investor RelatAug 22Option Exercise24.003,00072,00018,600Aug 26 09:45 AM
Aberman Michael SVP Strategy and Investor RelatAug 19Sale350.003,6111,263,85015,600Aug 19 04:16 PM
McCorkle Douglas SVP Controller and Asst TreasurAug 18Option Exercise52.035,875305,6768,875Aug 18 04:04 PM
Aberman Michael SVP Strategy and Investor RelatAug 18Option Exercise52.038,750455,26324,350Aug 19 04:16 PM
McCorkle Douglas SVP Controller and Asst TreasurAug 18Sale353.005,8752,073,8753,000Aug 18 04:04 PM
BROWN MICHAEL SDirectorAug 15Option Exercise33.423,000100,2603,000Aug 18 04:02 PM
BROWN MICHAEL SDirectorAug 15Sale349.203,0001,047,6000Aug 18 04:02 PM
GOLDSTEIN JOSEPH LDirectorAug 14Sale347.652,000695,3006,000Aug 14 04:14 PM
VAGELOS P ROYChairman of the BoardAug 13Sale340.018,0282,729,600248,540Aug 14 04:15 PM
VAGELOS P ROYChairman of the BoardAug 11Sale340.059,3723,186,967256,568Aug 11 05:25 PM
STAHL NEILSVP Research and Development SAug 11Sale339.9611,6463,959,20413,527Aug 11 04:04 PM
VAGELOS P ROYChairman of the BoardAug 08Sale340.332,600884,858265,940Aug 11 05:25 PM
STAHL NEILSVP Research and Development SAug 08Sale340.642,100715,34025,173Aug 08 04:49 PM
VAGELOS P ROYChairman of the BoardAug 07Option Exercise9.49270,3522,565,640411,191Aug 11 05:25 PM
STAHL NEILSVP Research and Development SAug 07Sale340.49741252,30427,273Aug 08 04:49 PM
STAHL NEILSVP Research and Development SAug 06Option Exercise21.2535,000743,75048,527Aug 08 04:49 PM
GOLDSTEIN JOSEPH LDirectorAug 06Sale331.202,000662,4008,000Aug 06 04:11 PM
REGENERON PHARMACEUTICALS INC10% OwnerAug 05Buy17.00588,2359,999,9951,809,098Aug 05 05:39 PM